指南与共识炎症性肠病

将生物标志物整合入临床试验和临床路径作为炎症性肠病治疗靶点的途径

Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases.
指南 / 共识 · Gastroenterology · 2019-06-19

国际炎症性肠病研究组织旨在概述生物标志物用于注册试验和临床实践所需的定义、类别和操作特性。以粪便钙卫蛋白为例,文章提供了一套在IBD患者中开发和验证生物标志物的框架。文章指出,粪便钙卫蛋白水平尚未被验证为IBD活动的生物标志物,仅可作为疾病复发的预后因素。

要点

  • 黏膜愈合是确定疾病并发症风险最有效的终点。
  • 粪便钙卫蛋白水平尚未被验证为IBD活动的生物标志物。
  • 粪便钙卫蛋白水平仅可作为药物或手术治疗后缓解期患者疾病复发的预后因素。

核心结论

  • 粪便钙卫蛋白水平尚未被验证为IBD活动的生物标志物,仅可作为缓解期患者疾病复发的预后因素。
  • 黏膜愈合是确定疾病并发症风险最有效的终点。

研究设计与样本

  • 国际炎症性肠病研究组织回顾了国际学会指南、监管机构指导文件和生物标志物标准化报告指南,并结合关于IBD患者粪便钙卫蛋白水平的出版物。

主要发现

  • 没有终点被完全验证为疾病并发症风险的替代指标。
  • 粪便钙卫蛋白水平因缺乏技术和临床可靠性、作为内镜替代时的性能评估以及对疾病状态变化的反应性评估,尚未被验证为IBD活动的生物标志物。
  • 粪便钙卫蛋白水平仅可作为药物或手术治疗后缓解期患者疾病复发的预后因素。

临床怎么用

  • 粪便钙卫蛋白水平可用于药物或手术治疗后缓解期患者疾病复发的预后评估。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: There is no consensus on the best way to integrate biomarkers into inflammatory bowel disease (IBD) research and clinical practice. The International Organization for the Study of Inflammatory Bowel Disease aimed to outline biomarker definitions, categories, and operating properties required for their use in registration trials and clinical practice. Using fecal calprotectin as an example, we provide a framework for biomarker development and validation in patients with IBD. METHODS: We reviewed international society guidelines, regulatory agency guidance documents, and standardized reporting guidelines for biomarkers, in combination with publications on fecal calprotectin levels in patients with IBD. We assessed the validity of fecal calprotectin to serve as a surrogate biomarker of IBD activity and outlined a framework for further validation and development of biomarkers. RESULTS: No endpoints have been fully validated as surrogates of risk of disease complications; mucosal healing is the most valid endpoint used to determine risk of disease complications. Fecal level of calprotectin has not been validated as a biomarker for IBD activity because of lack of technical and clinical reliability, assessment of performance when used as a replacement for endoscopy, and assessment of responsiveness to changes in disease states. The level of fecal calprotectin can be used only as a prognostic factor for disease recurrence in patients in remission after medical or surgical treatment. CONCLUSIONS: We reviewed guidelines, regulatory documents, and publications to identify properties required for the development of biomarkers of IBD activity and areas in need of clarification from regulatory agencies and societies. We propose a path forward for research of biomarkers for IBD.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Dulai PS, Peyrin-Biroulet L, Danese S, et al. Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases. Gastroenterology. 2019. PMID: 31228441. doi:10.1053/j.gastro.2019.06.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。